Long af­ter first nod for in­haled Ty­va­so, Unit­ed Ther­a­peu­tics scraps PhI­II in PH with COPD

Af­ter a re­cent court win for its in­haled pul­monary ar­te­r­i­al hy­per­ten­sion drug, push­ing off com­pe­ti­tion for a few more years, Unit­ed Ther­a­peu­tics has qui­et­ly scrapped a late-stage study of Ty­va­so.

The Phase III ter­mi­na­tion oc­curred be­cause of a rec­om­men­da­tion from the da­ta safe­ty mon­i­tor­ing com­mit­tee “fol­low­ing a rou­tine safe­ty and ef­fi­ca­cy analy­sis,” Unit­ed said in an SEC fil­ing Tues­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER